Tudor Investment Corp
JUNO

Tudor Investment Corp’s Juno Therapeutics, Inc. JUNO Stock Holding History

Tudor Investment Corp’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-20,305
Closed -$911K – 1413
2017
Q3 		$911K Buy
+20,305
New +$692K 0.02% 430
2017
Q1 		– Sell
-11,400
Closed -$215K – 1645
2016
Q4 		$215K Buy
+11,400
New +$279K 0.01% 1192
2016
Q1 		– Sell
-5,176
Closed -$228K – 2100
2015
Q4 		$228K Buy
+5,176
New +$257K 0.01% 1378
2015
Q3 		– Sell
-6,282
Closed -$335K – 1863
2015
Q2 		$335K Buy
6,282
+2,149
+52% +$114K 0.01% 1043
2015
Q1 		$251K Sell
4,133
-56,498
-93% -$2.74M 0.01% 1158
2014
Q4 		$3.17M Buy
+60,631
New +$2.71M 0.11% 99

Other funds holding JUNO

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Tudor Investment Corp's JUNO Position: Q4 2017 in Review

Tudor Investment Corp sold out of Juno Therapeutics, Inc. (JUNO) in Q4 2017, closing a stake of 20,305 shares — an estimated $911K sold.

Tudor Investment Corp first reported a position in JUNO in Q4 2014 and held it in 6 quarters. The position peaked at $3.17M in Q4 2014. 237 funds tracked by Wall St. Rank hold JUNO as of Q4 2017.

  • Tudor Investment Corp reported no remaining Juno Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
  • Tudor Investment Corp sold 20,305 Juno Therapeutics, Inc. shares in Q4 2017, an estimated $911K.
  • Tudor Investment Corp first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 6 quarters.
  • Tudor Investment Corp's Juno Therapeutics, Inc. position peaked at $3.17M in Q4 2014.
  • 237 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q4 2017.

Based on Tudor Investment Corp's 13F filing for Q4 2017, filed 14 Feb 2018.